Table 1

Histopathological and immunohistochemical data (median values and IQR (Q1–Q3)) before and after RTX or placebo therapy

	Placebo (n=9)			RTX-treated (n=16)
	Baseline	Week 12	p Value	Baseline	Week 12	p Value
Focus score	1.63 (0.84–3.27)	1.97 (1.47–2.88)	0.678	1.7 (0.87–2.5)	1.19 (0.59–1.23)	0.179
LELs/mm²	0.77 (0.38–1.05)	1.11 (0.67–1.23)	0.310	0.48 (0.24–0.91)	0.18 (0–0.42)	*0.011*
GCs/mm²	0.06 (0–0.23)	0.09 (0.03–0.15)	0.735	0.07 (0–0.28)	0 (0–0.1)	*0.004*
CD45 (%)	15.2 (5.86–16.92)	14.8 (5.2–28.06)	0.374	7.45 (1.85–22.35)	3.96 (0.48–7.71)	*0.011*
CD20+ cells/mm²	2709 (1469–4395)	3664 (2256–7979)	0.173	1172 (389–5278)	355 (51–743)	*0.001*
CD3+ cells/mm²	863 (359–1483)	1712 (725–2878)	0.953	315 (124–2157)	180 (91–570)	0.535

GCs, germinal centres; LEL, lymphoepithelial lesions; RTX, rituximab.
Bold typeface indicates the group of patients (placebo or RTX treated) and time point (baseline or week 12). Bold italic typeface indicates statistically significant results.